Stock Financial Ratios, Dividends, Split History
NS / NuStar Energy L.P. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||2,198.19|
|Enterprise Value ($M)||6,242.21|
|Book Value ($M)||2,492.06|
|Book Value / Share||26.74|
|Price / Book||0.88|
|NCAV / Share||n/a|
|Price / NCAV||n/a|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1110805|
|67058H902 067058H10 67058H952|
|SIC 461 - Pipelines, Except Natural Gas|
Stock splits are used by NuStar Energy L.P. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
2018-07-09 - Asif
Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...
2018-07-06 - Asif
Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...
Related News Stories
Teekay Corporation has been one of my largest personal holdings, largely based upon their control of Teekay LNG Partners. (20-0)
There is a shortage of truck drivers and low unemployment is making them difficult to replace. (5-0)
Distribution coverage is barely there, and would not be there without general partner support. Covenant violations would have occurred without that aid. (5-0)
In a rising broad market and a mixed commodity price backdrop, midstream stocks traded up but lagged the S&P 500 and utilities this week. Recent midstream corporation and utility outperformance has helped the Alerian Energy Infrastructure Index (AMEI) cut into the YTD lead the Alerian MLP Index has maintained since the MLP spike in January. (11-0)
Midstream and MLPs traded well this week, but not as well as you'd expect given a 5%+ oil move and strength in income securities (like utilities). The OPEC meeting Friday turned out to be a catalyst despite no surprise, because of how well-managed expectations were. Oil, energy stocks and MLPs were sharply higher Friday, and the Dow finished positive for the first time in 9 days. (62-0)
as of ET